4 terminated. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 4 |
| Phase 1 | 1 | Terminated 1 |
Follow CLL: new trials by email Literature Review of CLL trials Research Report on CLL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL TP-0903, TP-0903 and ibrutinib combination therapy - Chronic Lymphocytic Leukemia, CLL | Phase 1 / Phase 2 | Terminated | Sumitomo Pharma America, Inc. | 3 | 2019-06-10 | 2023-11-09 |
| Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) A6 - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Terminated | Ångstrom Pharmaceuticals | 5 | 2014-02-01 | 2016-07-13 |
| A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY) - Hematologic Malignancy, Leukemia | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 4 | 2012-03-01 | 2025-05-04 |
| Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL Ofatumumab, High-Dose Methylprednisolone, Alemtuzumab - CLL, SLL | Phase 2 | Terminated | Dana-Farber Cancer Institute | 30 | 2011-12-01 | 2023-08-29 |
Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia (2) · Lymphoma (2) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1) · Neoplasms, Plasma Cell (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Chronic Disease (3) · Disease Attributes (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Leukemia, B-Cell (3) · Leukemia, Lymphoid (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms by Histologic Type (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Neoplasms (2) · Leukemia (1)
Alemtuzumab (1) · Cyclophosphamide (1) · Methylprednisolone (1) · Mycophenolic Acid (1) · Radiotherapy (1) · Stem Cell Transplantation (1) · Tacrolimus (1) · Whole-Body Irradiation (1) · dubermatinib (1) · ofatumumab (1)
Dana-Farber Cancer Institute (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Sumitomo Pharma America, Inc. (1) · Ångstrom Pharmaceuticals (1)
United States (4)
Dolores Grosso, DNP, CRNP (1) · Jennifer R Brown, MD PhD (1) · Michael Choi, MD (1) · Neal Flomenberg, MD (1) · Phillip Komarnitsky (1)